Hypertension affects > 65 million people in the United States and is one of the leading causes of death. One to two percent of patients with hypertension have acute elevations of BP that require urgent medical treatment. Depending on the degree of BP elevation and presence of end-organ damage, severe hypertension can be defined as either a hypertensive emergency or a hypertensive urgency. A hypertensive emergency is associated with acute end-organ damage and requires immediate treatment with a titratable short-acting IV antihypertensive agent. Severe hypertension without acute end-organ damage is referred to as a hypertensive urgency and is usually treated with oral antihypertensive agents. This article reviews definitions, current concepts, common misconceptions, and pitfalls in the diagnosis and management of patients with acutely elevated BP as well as special clinical situations in which BP must be controlled.

Key words: aortic dissection; β-blockers; calcium-channel blockers; clevidipine; eclampsia; fenoldopam; hypertension; hypertensive crises; hypertensive encephalopathy; labetalol; nicardipine; nitroprusside; pre-eclampsia; pregnancy

Abbreviations: ACE = angiotensin-converting enzyme; APH = acute postoperative hypertension; DBP = diastolic BP; FDA = Food and Drug Administration; JNC = Joint National Committee; MAP = mean arterial pressure; SBP = systolic BP

Hypertension is one of the most common chronic medical conditions in the United States, affecting close to 30% of the population > 20 years old.1 While chronic hypertension is an established risk factor for cardiovascular, cerebrovascular, and renal disease, acute elevations in BP can result in acute end-organ damage with significant morbidity. Hypertensive emergencies and hypertensive urgencies (see definitions below) are commonly encountered by a wide variety of clinicians. Prompt recognition, evaluation, and appropriate treatment of these conditions are crucial to prevent permanent end-organ damage. This article reviews our current understanding of hypertensive crises, the common misconceptions and pitfalls in its diagnosis and management, as well as pharmacotherapy and special situations that clinicians may encounter.

DEFINITIONS

The classification and approach to hypertension undergoes periodic review by the Joint National Committee (JNC) on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, with the most recent report (JNC 7) having been released in 2003 (Table 1).2 Although not specifically addressed in the JNC 7 report, patients with a systolic BP (SBP) > 179 mm Hg or a diastolic BP (DBP) > 109 mm Hg are usually considered to be having a “hypertensive crisis.” The 1993 report3 of the JNC proposed an operational classification of hypertensive crisis as either “hypertensive emergencies” or “hypertensive urgencies.” This classification remains useful today. Severe elevations in BP were classified...
as hypertensive emergencies in the presence of acute end-organ damage, or as hypertensive urgencies in the absence of acute target-organ involvement. Distinguishing hypertensive urgencies from emergencies is important in formulating a therapeutic plan. Patients with hypertensive urgency should have their BP reduced within 24 to 48 h, whereas patients with hypertensive emergency should have their BP lowered immediately, although not to “normal” levels. The term malignant hypertension has been used to describe a syndrome characterized by elevated BP accompanied by encephalopathy or acute nephropathy.4 This term, however, has been removed from National and International Blood Pressure Control guidelines and is best referred to as a hypertensive emergency.

**Epidemiology**

Hypertensive emergencies were first described by Volhard and Fahr5 in 1914, who saw patients with severe hypertension accompanied by signs of vascular injury to the heart, brain, retina, and kidney. This syndrome had a rapidly fatal course, ending in heart attack, renal failure, or stroke. It was not, however, until 1939 when the first large study6 of the natural history of hypertensive emergencies was published. The results of this seminal article by Keith and colleagues6 revealed that untreated hypertensive emergencies had a 1-year mortality rate of 79%, with a median survival of 10.5 months. Prior to the introduction of antihypertensive medications, approximately 7% of hypertensive patients had a hypertensive emergency. Currently, it is estimated that 1 to 2% of patients with hypertension will have a hypertensive emergency at some time in their life.8,9

In the United States, hypertensive emergencies continue to be quite common, and the epidemiology of this disorder parallels the distribution of essential hypertension, being higher among the elderly and African Americans, with men being affected two times more frequently than women.10,11 Despite the development of increasingly effective antihypertensive treatments over the past 4 decades, the incidence of hypertensive emergencies has increased.12

The vast majority of patients presenting with a hypertensive emergency to an emergency department have a previous diagnosis of hypertension and have been prescribed antihypertensive agents.10,13 However, in many of these patients BP control prior to presentation was inadequate.13 The lack of a primary care physician, as well as the failure to adhere to prescribed antihypertensive regimens have been associated with the development of a hypertensive emergency.14,15 In some studies,15 > 50% of patients presenting to an emergency department with a hypertensive emergency were not adherent with their antihypertensive medication regimen in the preceding week. In both major metropolitan areas and smaller communities, illicit drug use has been reported14 to be a major risk factor for the development of hypertensive emergency.

**Pathophysiology**

Acute severe hypertension can develop de novo or can complicate underlying essential or secondary hypertension. The factors leading to the severe and rapid elevation of BP in patients with hypertensive crises are poorly understood. The rapidity of onset suggests a triggering factor superimposed on preexisting hypertension. Hypertensive crisis is thought to be initiated by an abrupt increase in systemic vascular resistance likely related to humoral vasoconstrictors.16,17 The subsequent increase in BP generates mechanical stress and endothelial injury leading to increased permeability, activation of the coagulation cascade and platelets, and deposition of fibrin. With severe elevations of BP, endothelial injury and fibrinoid necrosis of the arterioles ensue.16,17 This process results in ischemia and the release of additional vasoactive mediators generating a vicious cycle of ongoing injury. The renin-angiotensin system is often activated, leading to further vasoconstriction and the production of proinflammatory cytokines such as interleukin-6.18,19 The volume depletion that results from pressure natriuresis further simulates the release of vasoconstrictor substances from the kidney. These collective mechanisms can culminate in end-organ hypoperfusion, ischemia and dysfunction that manifests as a hypertensive emergency.

**Clinical Presentation**

Most patients have persistent BP elevation for years before they manifest a hypertensive emergency. The clinical manifestations of hypertensive emergency are directly related to the particular end-organ dysfunction that has occurred (Table 2).

### Table 1—JNC 7 BP Categorization*

<table>
<thead>
<tr>
<th>BP Class</th>
<th>SBP, mm Hg</th>
<th>DBP, mm Hg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>&lt; 120</td>
<td>&lt; 80</td>
</tr>
<tr>
<td>Prehypertension</td>
<td>121–139</td>
<td>80–89</td>
</tr>
<tr>
<td>Stage I</td>
<td>140–159</td>
<td>90–99</td>
</tr>
<tr>
<td>Stage II</td>
<td>≥ 160</td>
<td>≥ 100</td>
</tr>
</tbody>
</table>

*From Chobanian et al.2
Table 2—Clinical Manifestation of Hypertensive Emergencies*

<table>
<thead>
<tr>
<th>Hypertensive encephalopathy</th>
<th>Acute aortic dissection</th>
<th>Acute myocardial infarction</th>
<th>Acute coronary syndrome</th>
<th>Pulmonary edema with respiratory failure</th>
<th>Severe pre-eclampsia, HELLP syndrome, eclampsia</th>
<th>Acute renal failure</th>
<th>Microangiopathic hemolytic anemia</th>
<th>APH</th>
</tr>
</thead>
</table>

*HELPP = hemolysis, elevated liver enzymes, low platelets.

The signs and symptoms therefore vary from patient to patient. Zampaglione and colleagues reported that the most frequent presenting signs in patients with hypertensive emergencies were chest pain (27%), dyspnea (22%), and neurologic deficits (21%). No particular BP threshold has been associated with the development of a hypertensive emergency. However, organ dysfunction is uncommon with a DBP < 130 mm Hg (except in children and pregnancy). The absolute level of BP may not be as important as the rate of increase. For example, in patients with long-standing hypertension, a SBP of 200 mm Hg or a DBP up to 150 mm Hg may be well tolerated without the development of hypertensive encephalopathy; whereas in children and pregnant women, encephalopathy may develop with a DBP of only 100 mm Hg.

Initial Evaluation

Patients with hypertensive emergency usually present for evaluation as a result of a new symptom complex related to their elevated BP. Patient triage and physician evaluation should proceed expeditiously to prevent ongoing end-organ damage. A focused medical history that includes the use of any prescribed or over-the-counter medications should be obtained. If the patient is known to have hypertension, their hypertensive history, previous control, and current antihypertensive medications with dosing, adherence with their medication regimen, and the time from last dose are important facts to acquire prior to initiating treatment. Inquiry into the use of recreational drugs (amphetamine, cocaine, phencyclidine) or monoamine oxidase inhibitors should be made. Confirmation of the BP should be obtained by a physician in both arms using an appropriate-size BP cuff. The appropriate-size cuff is particularly important because the use of a cuff too small for the arm has been shown to artificially elevate BP readings in obese patients.

The physical examination should attempt to identify evidence of end-organ damage by assessing pulses in all extremities, auscultating the lungs for evidence of pulmonary edema, the heart for murmurs or gallops, the renal arteries for bruits, and performing a focused neurologic and fundoscopic examination. Headache and altered level of consciousness are the usual manifestations of hypertensive encephalopathy. Focal neurologic findings, especially lateralizing signs, are uncommon in hypertensive encephalopathy, being more suggestive of a cerebrovascular accident. Subarachnoid hemorrhage should be considered in patients with a sudden onset of a severe headache. The ocular examination may show evidence of advanced retinopathy with arteriolar changes, exudates, hemorrhages, or papilledema assisting in the identification of hypertensive encephalopathy.

If the clinical picture is consistent with aortic dissection (severe chest pain, unequal pulses, widened mediastinum), a contrast CT scan or MRI of the chest should be obtained promptly to rule out aortic dissection. Although transesophageal echocardiography has excellent sensitivity and specificity for aortic dissection, this study should not be performed until adequate blood control has been achieved. In patients presenting with pulmonary edema, it is important to obtain an echocardiogram to distinguish between diastolic dysfunction and mitral regurgitation.

Initial Management of BP

The majority of patients in whom severe hypertension (SBP > 160 mm Hg, DBP > 110 mm Hg) is identified on initial evaluation will have no evidence of end-organ damage and thus have a hypertensive urgency. Since no acute end-organ damage is present, these patients may present for evaluation of another complaint, and the elevated BP may represent an acute recognition of chronic hypertension. In these patients, utilizing oral medications to lower the BP gradually over 24 to 48 h is the best approach to management. Rapid reduction of BP may be associated with significant morbidity in hypertensive ur-
gency due to a rightward shift in the pressure/flow autoregulatory curve in critical arterial beds (cerebral, coronary, renal).29 Rapid correction of severely elevated BP below the autoregulatory range of these vascular beds can result in marked reduction in perfusion causing ischemia and infarction. Therefore, although the BP must be reduced in these patients, it must be lowered in a slow and controlled fashion to prevent organ hypoperfusion.

Altered autoregulation also occurs in patients with hypertensive emergency, and since end-organ damage is present already, rapid and excessive correction of the BP can further reduce perfusion and propagate further injury. Therefore, patients with a hypertensive emergency are best managed with a continuous infusion of a short-acting, titratable antihypertensive agent. Due to unpredictable pharmacodynamics, the sublingual and IM route should be avoided. Patients with a hypertensive emergency should be managed in an ICU with close monitoring. For those patients with the most severe clinical manifestations or with the most labile BP, intraarterial BP monitoring may be prudent. There are a variety of rapid-acting IV agents that are available for use in patients with hypertensive emergency, and the agent of choice depends on which manifestation of end-organ damage is present and the available monitored setting (Table 3). Rapid-acting IV agents should not be used outside of an ICUs monitored setting to prevent precipitous falls of BP that may have significant morbidity or mortality. The immediate goal is to reduce DBP by 10 to 15% or to approximately 110 mm Hg over a period of 30 to 60 min. In patients with aortic dissection, the BP should be reduced rapidly (within 5 to 10 min), targeting a SBP of < 120 mm Hg and mean arterial pressure (MAP) < 80 mm Hg.30,31 Once there is stable BP control with IV agents and end-organ damage has ceased, oral therapy can be initiated as the IV agents are slowly titrated down. An important consideration prior to initiating IV therapy is to assess the patient’s volume status. Due to pressure natriuresis, patients with hypertensive emergencies may be volume depleted, and restoration of intravascular volume with IV saline solution will serve to restore organ perfusion and prevent a precipitous fall in BP when antihypertensive regimens are initiated.

**Pharmacologic Agents Used in the Treatment of Hypertensive Emergencies**

A number of drugs are available for the management of hypertensive emergency. The agent of choice in any particular situation will depend on the clinical presentation (Table 3). The preferred agents include labetalol, esmolol, nicardipine, and fenoldopam. Phenolamine and trimethaphan camysylate are less commonly used today; however, they may be useful in particular situations such as catecholamine-induced hypertensive crises (ie, pheochromocytoma). Sodium nitroprusside may be used in patients with acute pulmonary edema and/or severe left ventricular dysfunction and in patients with aortic dissection.32 Oral and sublingual nifedipine are potentially dangerous in patients with hypertensive emergencies and are not recommend. Clonidine and angiotensin-converting enzyme (ACE) inhibitors are long acting and poorly titratable; however, these agents may be useful in the management of hypertensive urgencies. ACE inhibitors are contraindicated in pregnancy.33,34 Clevidipine is a relatively new agent under investigation for the management of postoperative hypertension and hypertensive emergencies.35 At this time, clevidipine is not available in the United States for use outside of clinical

---

**Table 3—Recommended Antihypertensive Agents for Hypertensive Crises**

<table>
<thead>
<tr>
<th>Conditions</th>
<th>Preferred Antihypertensive Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute pulmonary edema/systolic dysfunction</td>
<td>Nicardipine, fenoldopam, or nitroprusside in combination with nitroglycerin and a loop diuretic</td>
</tr>
<tr>
<td>Acute pulmonary edema/diastolic dysfunction</td>
<td>Esmolol, metoprolol, labetalol, or verapamil in combination with low-dose nitroglycerin and a loop</td>
</tr>
<tr>
<td>Acute myocardial ischemia</td>
<td>Labetalol or esmolol in combination with nitroglycerin</td>
</tr>
<tr>
<td>Hypertensive encephalopathy</td>
<td>Nicardipine, labetalol, or fenoldopam</td>
</tr>
<tr>
<td>Acute aortic dissection</td>
<td>Labetalol or combination of nicardipine and esmolol in combination with nitroprusside with either</td>
</tr>
<tr>
<td>Pre-eclampsia, eclampsia</td>
<td>esmolol or IV metoprolol</td>
</tr>
<tr>
<td>Acute renal failure/microangiopathic anemia</td>
<td>Labetalol or nicardipine</td>
</tr>
<tr>
<td>Sympathetic crisis/cocaine overdose</td>
<td>Verapamil, diltiazem, or nicardipine in combination with a benzodiazepine</td>
</tr>
<tr>
<td>APH</td>
<td>Esmolol, nicardipine, or labetalol</td>
</tr>
<tr>
<td>Acute ischemic stroke/intracerebral bleed</td>
<td>Nicardipine, labetalol, or fenoldopam</td>
</tr>
</tbody>
</table>

---

Postgraduate Education Corner
trials. The recommended IV antihypertensive agents are reviewed briefly below. Dosage and adverse effects of commonly used parenteral antihypertensive medications are listed in Table 4.

**Labetalol**

Labetalol is a combined selective α1-adrenergic and nonselective β-adrenergic receptor blocker with an α- to β-blocking ratio of 1:7.36 Labetalol is metabolized by the liver to form an inactive glucuronide conjugate.37 The hypotensive effect of labetalol begins within 2 to 5 min after its IV administration, reaching a peak at 5 to 15 min following administration, and lasting for about 2 to 4 h.37,38 Due to its β-blocking effects, the heart rate is either maintained or slightly reduced. Unlike pure β-adrenergic blocking agents that decrease cardiac output, labetalol maintains cardiac output.39 Labetalol reduces the systemic vascular resistance without reducing total peripheral blood flow. In addition, the cerebral, renal, and coronary blood flow are maintained.39–42 This agent has been used in the setting of pregnancy-induced hypertensive crisis because little placental transfer occurs mainly due to the negligible lipid solubility of the drug.36

Labetalol may be administered as loading dose of 20 mg, followed by repeated incremental doses of 20 to 80 mg at 10-min intervals until the desired BP is achieved. Alternatively, after the initial loading dose, an infusion commencing at 1 to 2 mg/min and titrated up to until the desired hypotensive effect is achieved is particularly effective. Bolus injections of 1 to 2 mg/kg have been reported to produce precipitous falls in BP and should therefore be avoided.43

**Nicardipine**

Nicardipine is a second-generation dihydropyridine derivative calcium-channel blocker with high vascular selectivity and strong cerebral and coronary vasodilatory activity. The onset of action of IV nicardipine is from 5 to 15 min, with a duration of action of 4 to 6 h. IV nicardipine has been shown to reduce both cardiac and cerebral ischemia.44 The nicardipine dosage is independent of the patient’s weight, with an initial infusion rate of 5 mg/h, increasing by 2.5 mg/h every 5 min to a maximum of 15 mg/h until the desired BP reduction is achieved.21 A useful therapeutic benefit of nicardipine is that the agent has been demonstrated to increase both stroke volume and coronary blood flow with a favorable effect on myocardial oxygen balance.44–48 This property is useful in patients with coronary artery disease and systolic heart failure.

**Esmolol**

Esmolol is an ultrashort-acting cardioselective, β-adrenergic blocking agent.49–51 The onset of action of this agent is within 60 s, with a duration of action of 10 to 20 min.49–51 The metabolism of esmolol is via rapid hydrolysis of ester linkages by RBC esterases and is not dependant on renal or hepatic function. Due to its pharmacokinetic properties, some authors21 consider it an “ideal β-adrenergic blocker” for use in critically ill patients. This agent is available for IV use both as a bolus and as an infusion. Esmolol is particularly useful in severe postoperative hypertension.52–56 Esmolol is a suitable agent in situations in which cardiac output, heart rate, and BP are increased. Typically, the drug

### Table 4—Dosage and Adverse Effects of Commonly Used Parenteral Antihypertensive Medications

<table>
<thead>
<tr>
<th>Agents</th>
<th>Dosage</th>
<th>Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enalapril</td>
<td>1.25 mg over 5 min every 4 to 6 h, titrate by 1.25-mg increments at 12- to 24-h intervals to maximum of 5 mg q6h</td>
<td>Variable response, potential hypotension in high renin states, headache, dizziness</td>
</tr>
<tr>
<td>Esmolol</td>
<td>500 μg/kg loading dose over 1 min, infusion at 25 to 50 μg/kg/min, increased by 25 μg/kg/min every 10 to 20 min to maximum of 300 μg/kg/min</td>
<td>Nausea, flushing, first-degree heart block, infusion site pain</td>
</tr>
<tr>
<td>Fenoldopam</td>
<td>0.1 μg/kg/min initial dose, 0.05 to 0.1 μg/kg/min increments to maximum of 1.6 μg/kg/min</td>
<td>Nausea, headache, flushing</td>
</tr>
<tr>
<td>Labetalol</td>
<td>20-mg initial bolus, 20- to 80-mg repeat boluses or start infusion at 2 mg/min with maximum 24-h dose of 300 mg</td>
<td>Hypotension, dizziness, nausea/vomiting, paresthesias, scalp tingling, bronchospasm</td>
</tr>
<tr>
<td>Nicardipine</td>
<td>5 mg/h, increase at 2.5 mg/h increments every 5 min to maximum of 15 mg/h</td>
<td>Headache, dizziness, flushing, nausea, edema, tachycardia</td>
</tr>
<tr>
<td>Nitroglycerin</td>
<td>5 μg/min, titrated by 5 μg/min every 5 to 10 min to maximum of 60 μg/min</td>
<td>Headache, dizziness, tachyphylaxis</td>
</tr>
<tr>
<td>Nitropresside</td>
<td>0.5 μg/kg/min, increase to maximum of 2 μg/kg/min to avoid toxicity</td>
<td>Thiocyanate and cyanide toxicity, headache, nausea/vomiting, muscle spasm, flushing</td>
</tr>
<tr>
<td>Phenolamine</td>
<td>1- to 5-mg boluses, maximum 15-mg dose</td>
<td>Flushing, tachycardia, dizziness, nausea/vomiting</td>
</tr>
</tbody>
</table>
is administered as a 0.5 to 1 mg/kg loading dose over 1 min, followed by an infusion starting at 50 μg/kg/min and increasing up to 300 μg/kg/min as necessary.

**Fenoldopam**

Fenoldopam is unique among the parenteral BP agents because it mediates peripheral vasodilation by acting on peripheral dopamine-1 receptors. Fenoldopam is rapidly and extensively metabolized by conjugation in the liver, without participation of cytochrome P-450 enzymes. The onset of action is within 5 min, with the maximal response being achieved by 15 min. No adverse effects have been reported. An initial starting dose of 0.1 μg/kg/min is recommended. Fenoldopam improves creatinine clearance, urine flow rates, and sodium excretion in severely hypertensive patients with both normal and impaired renal function. The use of fenoldopam as a prophylactic agent to prevent contrast-induced nephropathy has been disappointing.

**Nitroprusside**

Sodium nitroprusside is an arterial and venous vasodilator that decreases both afterload and preload. Nitroprusside decreases cerebral blood flow while increasing intracranial pressure, effects that are particularly disadvantageous in patients with hypertensive encephalopathy or following a cerebrovascular accident. In patients with coronary artery disease, a significant reduction in regional blood flow (coronary steal) can occur. In a large randomized, placebo-controlled trial, nitroprusside was shown to increase mortality when infused in the early hours after acute myocardial infarction (mortality at 13 weeks, 24.2% vs 12.7%). Nitroprusside is a very potent agent, with an onset of action of seconds, a duration of action of 1 to 2 min, and a plasma half-life of 3 to 4 min. Due to its potency, rapidity of action, and the development of tachyphylaxis, we recommend intraarterial BP monitoring. In addition, sodium nitroprusside requires special handling to prevent its degradation by light. These factors limit the use of this drug.

Nitroprusside contains 44% cyanide by weight. Cyanide is released nonenzymatically from nitroprusside, the amount generated being dependent on the dose of nitroprusside administered. Cyanide is metabolized in the liver to thiocyanate. Thiocyanate is required for this reaction. Thiocyanate is 100 times less toxic than cyanide. The thiocyanate generated is excreted largely through the kidneys. Cyanide removal therefore requires adequate liver function, adequate renal function, and adequate bioavailability of thiosulfate. Nitroprusside may therefore cause cytotoxicity due to the release of cyanide with interference of cellular respiration. Cyanide toxicity has been documented to result in “unexplained cardiac arrest,” coma, encephalopathy, convulsions, and irreversible focal neurologic abnormalities. The current methods of monitoring for cyanide toxicity are insensitive. Metabolic acidosis is usually a preterminal event. In addition, a rise in serum thiocyanate levels is a late event and not directly related to cyanide toxicity. RBC cyanide concentrations (although not widely available) may be a more reliable method of monitoring for cyanide toxicity. An RBC cyanide concentration > 40 nmol/mL results in detectable metabolic changes. Levels > 200 nmol/L are associated with severe clinical symptoms, and levels > 400 nmol/L are considered lethal. Data suggest that nitroprusside infusion rates > 4 μg/kg/min, for as little as 2 to 3 h may lead to cyanide levels in the toxic range. The recommended doses of nitroprusside of up to 10 μg/kg/min results in cyanide formation at a far greater rate than human beings can detoxify. Sodium nitroprusside has also been demonstrated to cause cytotoxicity through the release of nitric oxide, with hydroxyl radical and peroxynitrite generation leading to lipid peroxidation.

Considering the potential for severe toxicity with nitroprusside, this drug should only be used when other IV antihypertensive agents are not available and then only in specific clinical circumstances and in patients with normal renal and hepatic function. The duration of treatment should be as short as possible, and the infusion rate should not be > 2 μg/kg/min. An infusion of thiosulfate should be used in patients receiving higher dosages (4 to 10 μg/kg/min) of nitroprusside.

**Clevidipine**

Clevidipine is third-generation dihydropyridine calcium-channel blocker that has been developed for use in clinical settings in which tight BP control is crucial. Clevidipine is an ultrashort-acting selective arteriolar vasodilator. Clevidipine acts by selectively inhibiting the influx of extracellular calcium through the L-type channel, relaxing smooth muscle of small arteries, and reducing peripheral vascular resistance. Similar to esmolol, it is rapidly metabolized by RBC esterases; thus, its metabolism is not affected by renal or hepatic function. Clevidipine reduces BP by a direct and selective effect on arterioles, thereby reducing afterload without affect-
ing cardiac filling pressures or causing reflex tachycardia.\textsuperscript{35} Stroke volume and cardiac output usually increase. Moreover, clevidipine has been shown to protect against ischemia/reperfusion injury in an animal model of myocardial ischemia and to maintain renal function and splanchic blood flow.\textsuperscript{87–89}

Several small trials\textsuperscript{90,91} have shown clevidipine to be very effective in the control of postoperative hypertension. Although no studies have investigated the role of this drug in hypertensive emergencies, its profile makes it a potentially ideal drug for this indication. At this time, clevidipine is not available in the United States for use outside of clinical trials.

Nifedipine, nitroglycerin, and hydralazine are not recommended in the management of hypertensive emergencies. The basis of these recommendations are discussed below.

**Nifedipine**

Nifedipine has been widely used via oral or sublingual administration in the management of hypertensive emergencies, severe hypertension associated with chronic renal failure, postoperative hypertension, and pregnancy-induced hypertension. Although nifedipine has been administered via the sublingual route, the drug is poorly soluble and is not absorbed through the buccal mucosa. It is however rapidly absorbed from the GI tract after the capsule is broken/dissolved.\textsuperscript{92} This mode of administration has not been approved by the US Food and Drug Administration (FDA). A significant decrease in BP is usually observed 5 to 10 min after nifedipine administration, with a peak effect from 30 to 60 min, and a duration of action of approximately 6 to 8 h.\textsuperscript{93}

Sudden uncontrolled and severe reductions in BP accompanying the administration of nifedipine may precipitate cerebral, renal, and myocardial ischemic events that have been associated with fatal outcomes.\textsuperscript{94} Elderly hypertensive patients with underlying organ impairment and structural vascular disease are more vulnerable to the rapid and uncontrolled reduction in arterial pressure. Given the seriousness of the reported adverse events and the lack of any clinical documentation attesting to a benefit, the use of nifedipine capsules for hypertensive emergencies and “pseudoemergencies”\textsuperscript{2} should be abandoned. The Cardiorenal Advisory Committee of the FDA has concluded that the practice of administering sublingual/oral nifedipine should be abandoned because this agent is not safe nor efficacious.\textsuperscript{95}

**Nitroglycerin, Hydralazine, and Diuretics**

Nitroglycerin is a potent venodilator and only at high doses affects arterial tone.\textsuperscript{96} It causes hypotension and reflex tachycardia, which are exacerbated by the volume depletion characteristic of hypertensive emergencies. Nitroglycerin reduces BP by reducing preload and cardiac output; undesirable effects in patients with compromised cerebral and renal perfusion. Low-dose administration (approximately 60 mg/min) may, however, be used as an adjunct to IV antihypertensive therapy in patients with hypertensive emergencies associated with acute coronary syndromes or acute pulmonary edema.

Hydralazine is a direct-acting vasodilator. Following IM or IV administration, there is an initial latent period of 5 to 15 min followed by a progressive and often precipitous fall in BP that can last up to 12 h.\textsuperscript{97,98} Although the circulating half-life of hydralazine is only approximately 3 h, the half-time of its effect on BP is approximately 10 h.\textsuperscript{99,100} Because of the prolonged and unpredictable antihypertensive effects of hydralazine and the inability to effectively titrate its hypotensive effect, it is best avoided in the management of hypertensive crises.

Volume depletion is common in patients with hypertensive emergencies, and the administration of a diuretic together with a hypertensive agent can lead to a precipitous drop in BP. Diuretics should be avoided unless specifically indicated for volume overload, as occurs in renal parenchymal disease or coexisting pulmonary edema.

**SPECIAL CONDITIONS**

**Acute Aortic Dissection**

Aortic dissection should be considered a likely diagnostic possibility in patients presenting to the emergency department with acute chest pain and elevated BP. Left untreated, approximately three fourths of patients with type A dissection (ascending aorta) die within 2 weeks of an acute episode, but with successful therapy the 5-year survival rate is 75%.\textsuperscript{30,101} Hence, timely recognition of this disease entity coupled with urgent and appropriate management is the key to a successful outcome in the majority of these patients. It is important to recognize that the propagation of the dissection is dependent not only on the elevation of the BP itself but also on the velocity of left ventricular ejection.\textsuperscript{30,31,101–103}

A vasodilator alone is not ideal in the treatment of acute aortic dissection because this can promote reflex tachycardia, increase aortic ejection velocity, and promote dissection propagation. The combination of a \(\beta\)-adrenergic antagonist and vasodilator is the standard approach to treatment.\textsuperscript{30,31} Esmolol is the \(\beta\)-adrenergic antagonist of choice with metoprolol as a suitable alternative.\textsuperscript{104,105} Although nitropruss-
side has traditionally been used as the vasodilator of choice, nicardipine or fenoldopam are less toxic, equally effective alternatives. All patients with aortic dissection require cardiovascular surgical consultation to determine if surgical management is necessary. Unless significant medical comorbidities are present, surgery is indicated for all patients with type A dissection. Patients with type B dissections and distal aortic dissections can be managed with aggressive BP control because outcomes have been shown to be the same with either medical or surgical treatment unless complications such as leak, rupture, or impaired flow to vital organs supervene.

Cerebrovascular Accidents

The vast majority of patients with cerebral ischemia present with acutely elevated BP regardless of the subtype of infarct or preexisting hypertension. The BP elevation decreases spontaneously over time. The elevated BP is not a manifestation of a hypertensive emergency but rather a protective physiologic response to maintain cerebral perfusion pressure to the vascular territory affected by ischemia. Lowering the BP in patients with ischemic strokes may reduce cerebral blood flow, which because of impaired autoregulation, may result in further ischemic injury. The common practice of “normalizing” the BP following a cerebrovascular accident is potentially dangerous. It should be noted that the Intravenous Nimodipine West European Trial for acute stroke was stopped because of increased neurologic deterioration in the treatment group, which the investigators attributed to the effects of hypotension.

The American Stroke Association and the European Stroke Initiative guidelines recommend withholding antihypertensive therapy for acute ischemic stroke unless there is planned thrombolysis, evidence of concomitant noncerebral acute organ damage, or if the BP is excessively high, arbitrarily chosen as a SBP > 220 mm Hg or a DBP > 120 mm Hg based on the upper limit of normal autoregulation. In these patients, the aim is to reduce the pressure by not more than 10 to 15% in the first 24 h.

In patients receiving thrombolytic therapy, antihypertensive therapy is required for SBP > 185 mm Hg or DBP > 110 mm Hg, with a targeted SBP of 150 mm Hg and a DBP of 105 mm Hg. The current American Heart Association guidelines recommend the use of labetalol or nicardipine if the SBP is > 220 mm Hg or the DBP is from 121 to 140 mm Hg, and nitroprusside for a DBP > 140 mm Hg. For the reasons outlined above, we believe nitroprusside to be a poor choice in patients with intracranial pathology. The Acute Candesartan Cilexetil Therapy in Stroke Survivors study demonstrated a reduction in 12-month mortality and the number of vascular events in patients with a SBP > 200 mm Hg or a DBP > 110 mm Hg who were treated with an angiotensin type 1 receptor blockade (candesartan cilexetil) immediately after an ischemic stroke. The mechanism(s) by which the angiotensin type 1 receptor blocker exerted its beneficial effects is unclear, as the BP profiles were nearly identical in the treatment and placebo groups. Additional studies are required to confirm the benefit of angiotensin type 1 receptor blockers in patients with ischemic stroke.

In patients with intracerebral hematomas, there is almost always a rise in intracranial pressure with reflex systemic hypertension. There is no evidence that hypertension provokes further bleeding in patients with intracranial hemorrhage. However, a precipitous fall in systemic BP will compromise cerebral perfusion. The controlled lowering of the BP is currently recommended only when the SBP is > 200 mm Hg, the DBP is > 110 mm Hg, or the MAP is > 130 mm Hg. A study has demonstrated that the rapid decline of BP within the first 24 h after presentation of an intracranial hemorrhage was associated with increased mortality; the rate of decline in BP was independently associated with increased mortality. Nicardipine has been demonstrated to be an effective agent for the control of BP in patients with intracerebral hemorrhage.

Preeclampsia and Eclampsia

Hypertension is one of the most common medical disorders affecting pregnancy. It complicates 12% of pregnancies and is responsible for 18% of maternal deaths in the United States. The presentation of a patient with pregnancy-induced hypertension may...
range from a mild to a life-threatening disease process. Initial therapy of preeclampsia includes volume expansion, magnesium sulfate (MgSO₄) for seizure prophylaxis and BP control. Delivery is the definitive treatment for preeclampsia and eclampsia.

Magnesium sulfate is usually administered as a loading dose of 4 to 6 g in 100 mL 5% dextrose in 1/4 normal saline solution over 15 to 20 min, followed by a constant infusion of 1 to 2 g/h of MgSO₄ depending on urine output and deep tendon reflexes, which are checked on an hourly basis. The next step in the management of preeclampsia is to reduce the BP to a safe range being diligent to avoid significant hypotension. The objective of treating severe hypertension is to prevent intracerebral hemorrhage and cardiac failure without compromising cerebral perfusion or jeopardizing uteroplacental blood flow, which is already reduced in many women with preeclampsia. Studies of women with mild preeclampsia have shown no benefit to antihypertensive therapy (labetalol or calcium-channel blockers) and suggested that antihypertensive therapy may increase the risk of intrauterine growth retardation. Antihypertensive therapy is therefore administered primarily to prevent complications in the mother. The Working Group Report on High Blood Pressure in Pregnancy recommends initiation of antihypertensive therapy for a DBP ≥ 105 mm Hg. Furthermore, most authorities and the current guidelines from the American College of Obstetricians and Gynecologists recommend keeping SBP from 140 to 160 mm Hg and DBP from 90 to 105 mm Hg. This recommendation is supported by a study that demonstrated that SBP > 160 mm Hg was the most important factor associated with a cerebrovascular accident in patients with severe preeclampsia and eclampsia. This would suggest that SBP from 155 to 160 mm Hg should be the primary trigger to initiate antihypertensive therapy in a patient with severe preeclampsia or eclampsia. It should be noted that patients with preeclampsia/eclampsia may have a very labile BP; this fact together with the narrow target BP range dictate that these patients be closely monitored in an ICU, preferably with an arterial catheter. Intracerebral hemorrhage is a devastating complication in these patients that can be avoided by scrupulous attention to BP control.

No antihypertensive medication is specifically approved by the FDA for use in pregnant women. Hydralazine has been recommended as the drug of choice to treat severe preeclampsia and eclampsia since the early 1970s. However, hydralazine has a number of properties that make it unsuitable for this indication. Its side effects (such as headache, nausea, and vomiting) are common and mimic symptoms of deteriorating preeclampsia. Most importantly, however, it has a delayed onset of action, an unpredictable hypotensive effect, and a prolonged duration of action. These properties may result in a precipitous hypotensive overshoot compromising both maternal cerebral blood flow and uteroplacental blood flow. Indeed, in a metaanalysis published by Magee and colleagues, hydralazine was associated with an increased risk of maternal hypotension that was associated with an excess of cesarean sections, placental abruptions, and low Apgar scores. Based on the available data, we suggest that hydralazine not be used as first-line treatment of severe hypertension in pregnancy. Similarly, sublingual or oral nifedipine should be avoided in this setting. Our preference is IV labetalol or nicardipine, which are easier to titrate and have a more predictable dose response than hydralazine. Both agents appear to be safe and effective in hypertensive pregnant patients. Nitroprusside and ACE inhibitors are contraindicated in pregnant patients.

**Sympathetic Crises**

The most commonly encountered sympathetic crises are related to the recreational use of sympathomimetic drugs such as cocaine, amphetamine, or phencyclidine. Rarely, these crises may be seen with pheochromocytoma, patients receiving a monoamine oxidase inhibitor who ingest a tyramine-containing food, or patients who abruptly stop antihypertensive medications such as clonidine or β-adrenergic antagonists.

In the clinical situations characterized by sympathetic overstimulation, β-adrenergic antagonists should be avoided to prevent vascular β-receptor antagonism resulting in unopposed α-adrenergic activity and potential increase in BP. In fact, in cocaine-induced hypertensive emergency, the use of β-adrenergic blockade can increase coronary vasoconstriction, fail to control heart rate, increase BP, and decrease survival. Interestingly, although labetalol is traditionally considered the ideal agent due to its α- and β-adrenergic antagonism, experimental studies do not support its use in this clinical setting. BP control is best achieved with nicardipine, fenoldopam, or verapamil in combination with a benzodiazepine. Phentolamine is an alternative agent.

**Acute Postoperative Hypertension**

Acute postoperative hypertension (APH) has been defined as a significant elevation in BP during the immediate postoperative period that may lead to serious neurologic, cardiovascular, or surgical-site
complications and that requires urgent management.\textsuperscript{161} Despite the widespread and long-standing recognition of APH, there is no agreement in the literature on a more precise quantitative definition.\textsuperscript{161–163} APH has an early onset, being observed within 2 h after surgery in most cases and is typically of short duration, with most patients requiring treatment for \( \leq 6 \) h. Postoperative complications of APH may include hemorrhagic stroke, cerebral ischemia, encephalopathy, myocardial ischemia, myocardial infarction, cardiac arrhythmia, congestive cardiac failure with pulmonary edema, failure of vascular anastomoses, and bleeding at the surgical site. Although APH may occur following any major surgery, it is most commonly associated with cardiothoracic, vascular, head and neck, and neurosurgical procedures. The pathophysiologic mechanism underlying APH is uncertain and may vary with the surgical procedure and other factors. However, the final common pathway leading to hypertension appears to be activation of the sympathetic nervous system, as evidenced by elevated plasma catecholamine concentrations in patients with APH.\textsuperscript{17} The primary hemodynamic alteration observed in APH is an increase in afterload with an increase in SBP and DBP with or without tachycardia.

There is no consensus concerning the treatment threshold for the management of noncardiac surgery patients with APH. Treatment is frequently a bedside decision by the anesthesiologist or surgeon that takes into consideration the baseline BP, concomitant disease, and the perceived risk of complications. In contrast, in cardiac surgery patients, treatment is recommended for a BP > 140/90 or a MAP of at least 105 mm Hg.\textsuperscript{161–163} Pain and anxiety are common contributors to BP elevations and should be treated before administration of antihypertensive therapy. Other potentially reversible causes of APH include hypothermia with shivering, hypoxemia, hypercarbia, and bladder distension. Short-term administration of a short-acting IV agent is recommended when there is no identifiable treatable cause of hypertension. Labetalol, esmolol, nicardipine, and clevidipine have proven effective in the management of APH.\textsuperscript{90,91,161,164–168}

Conclusions

Patients with hypertensive emergencies require the immediate reduction of the elevated BP to prevent and arrest progressive end-organ damage. The best clinical setting to achieve this BP control is in the ICU, with the use of titratable IV hypotensive agents. There are several antihypertensive agents available including esmolol, nicardipine, labetalol, and fenoldopam. While sodium nitroprusside is a rapid-acting and potent antihypertensive agent, it may be associated with significant toxicity and should therefore be used in select circumstances at a dose not to exceed 2 \( \mu \)g/kg/min. The appropriate therapeutic approach of each patient will depend on the clinical presentation of the patient. Agents such as nifedipine and hydralazine should be abandoned because these agents are associated with significant toxicities and/or side effect profile.

Acknowledgment: The author acknowledges the assistance of Susan Baik, RN, for her helpful critique and editorial assistance with this article.

References


26 Garcia JYJ, Vidt DG. Current management of hypertensive emergencies. Drugs 1987; 34:263–276


81 Göbbel GT, Chan TY, Chan PH. Nitric oxide- and superoxide-mediated toxicity in cerebral endothelial cells. J Pharmacol Exp Ther 1997; 282:1600–1607
89 Stephens CT, Jandhyala BS. Effects of fenoldopam, a dopamine D-1 agonist, and clevidipine, a calcium channel antagonist, in acute renal failure in anesthetized rats. Clin Exp Hypertension 2002; 24:301–313
97 Schroeder HA. Effects on hypertension of sulfhydril and hydrazine compounds. J Clin Invest 1951; 30:672–673
163 Weant KA, Flynn JD, Smith KM. Postoperative hypertension. Orthopedics 2004; 27:1159–1161